The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Rilpivirine Hydrochloride Drug Master File in Japan (Rilpivirine Hydrochloride JDMF) empowers Rilpivirine Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Rilpivirine Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Rilpivirine Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Rilpivirine Hydrochloride suppliers with JDMF on PharmaCompass.